Patents Examined by Marcos L Sznaidman
  • Patent number: 11026873
    Abstract: Described herein, are personal care compositions comprising taurine in combination with arginine and glycine, and methods for using the compositions to effect reduction of skin irritation and or inflammation, and/or improving barrier repair of the skin.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: June 8, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Zeenat Nabi, Shujiang Cheng, Halyna Siomyk, Laurence Du-Thumm
  • Patent number: 11028100
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Patent number: 11013705
    Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.
    Type: Grant
    Filed: March 14, 2020
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of California, Augusta University Research Institute
    Inventors: Thomas Weimbs, Jacob Torres, Muthusamy Thangaraju
  • Patent number: 11008331
    Abstract: 10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carboxylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof in preparation of medicaments for treatment of viral hepatitis B.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 18, 2021
    Assignee: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
    Inventors: Fei Sun, Jinhua Du, Yanbin Hu, Lili Zhou, Charles Z. Ding, Shuhhui Chen
  • Patent number: 11000543
    Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei Sun
  • Patent number: 10988480
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 27, 2021
    Assignee: Rhodes Technologies
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Patent number: 10987330
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 27, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10980761
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 20, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10980759
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 20, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10980760
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 20, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10973791
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: April 13, 2021
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10952987
    Abstract: The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. A method is also provided for treating a subject in need thereof by administering the combination of adrenaline with an antidepressant. The pharmaceutical composition is to be administered by injection.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOPROJET
    Inventors: Jean-Charles Schwartz, Xavier Ligneau, Laurent François Gérard Landais, David Perrin, Jeanne-Marie Lecomte
  • Patent number: 10954219
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: March 23, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu Kanno, Jun Watanabe, Takao Horiuchi, Akira Nakao, Keisuke Suzuki, Tomonori Yamasaki, Nobuaki Adachi, Daisuke Honma, Yoshito Hamada
  • Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Patent number: 10940205
    Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 9, 2021
    Assignee: THEMIS MEDICARE LIMITED
    Inventors: Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani, Madhavlal Govindlal Patel
  • Patent number: 10933031
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 2, 2021
    Assignees: The Trustees of Columbia University in the City of New York, Hadasit Medical Research Services and Development Ltd., Ramot at Tel-Aviv University, Ltd.
    Inventors: Hasan Orhan Akman, Salvatore Dimauro, Or Kakhlon, Miguel Enrique Weil
  • Patent number: 10933018
    Abstract: Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 2, 2021
    Assignee: Timber Pharmaceuticals LLC
    Inventors: Zachary Rome, Charles Rodney Greenaway Evans, Marc Barry Brown, Francesco Caserta
  • Patent number: 10925870
    Abstract: Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 23, 2021
    Assignee: Ohio State Innovation Foundation
    Inventors: Wolfgang Sadee, John Oberdick
  • Patent number: 10888564
    Abstract: The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: January 12, 2021
    Assignee: Institute for Cancer Research
    Inventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
  • Patent number: 10881636
    Abstract: Described is a dihydroartemisinin-steroid conjugate of formula (I), or a pharmaceutically acceptable salt thereof, where position 10 of dihydroartemisinin is linked to the steroid through a linker X. This application further provides a preparation method of the dihydroartemisinin-steroid conjugate and an application of the dihydroartemisinin-steroid conjugate in the preparation of a drug for treating cancer. The dihydroartemisinin-steroid conjugate of the invention exhibits potent inhibitory activity against various tumor cells and low cytotoxicity, moreover, the conjugate is capable of penetrating the blood-brain barrier, having a broad application prospect.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: January 5, 2021
    Assignee: YUNBAIYAO ZHENGWU SCIENCE AND TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Jinghua Zhang, Zhengwu Shen